Z-Medica is the home of the innovative blood clotting technology behind QuikClot® family of products for hemostasis. Z-Medica was founded in 2002 by Francis X. Hursey, a veteran of the Apollo Project Breathing Air Team.
Z-Medica manufactures the QuikClot® family of hemostatic products. QuikClot promotes clotting within minutes from application and is safe, effective and easy to use. QuikClot is designed for use by Healthcare Professionals, First Responders, Law Enforcement Officers, Consumers and the Military. QuikClot Combat Gauze® is the only hemostatic agent recommended by the Department of Defense for all branches of the U.S. Military for severe hemorrhage on the battlefield.
How Quik-Clot works
Healthcare Professionals click here
EMS click here
Law Enforcement click here
Military click here
QuikClot products are now in their third generation and are impregnated with a mineral called kaolin that has been clinically shown to accelerate the body's natural coagulation cascade. Kaolin is a naturally-occurring, inorganic mineral that does not contain any botanicals, biological material or shellfish products and does not cause any exothermic reaction or vascular complications. QuikClot products are credited with helping thousands of people survive traumatic blood loss every year.
It has been known for many years that the intrinsic blood clotting pathway is inititiated by negatively charged surfaces such as kaolin or glass. Kaolin is utilized routinely in reagents that are used to assay blood clotting times by clinical laboratories that follow procedures that are published by the College of American Pathologists (CAP).
Kaolin is an inert mineral and it promotes clotting by two main modes of action:
• Kaolin promotes the activation of Factor XII (FXII) in the presence of kallikrein and high molecular weight kininogen. Activated FXII initiates the intrinsic clotting pathway via the activation of Factor XI. Activated FXI continues the coagulation pathway that ends with the formation of a fibrin clot.
• Kaolin promotes the activation of platelet-associated FXI and it is a distinct and separate molecule from plasma FXI. Activated platelet-associated FXI initiates the intrinsic clotting pathway in normal and FXII deficient patients.
Blood Coagulation Pathways